A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma
Status:
Terminated
Trial end date:
2017-12-27
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, non-randomized study. Patients will receive ASP7487
(OSI-906) in combination with bortezomib and dexamethasone. Phase 1 involves dose escalation
of the combination, whereas Phase 2 involves the expansion of ASP7487 (OSI-906) combined with
bortezomib and dexamethasone at the MTD to establish the ORR. This trial will accrue patients
with relapsed or relapsed/refractory MM - a disease state for which bortezomib is approved to
treat by the FDA and Health Canada. The combination of ASP7487 (OSI-906) with bortezomib is
supported by pre-clinical work in MM in which the combination with an IGF1-R inhibitor
enhances anti-tumor activity of bortezomib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Astellas Pharma Inc Multiple Myeloma Research Consortium